Litigation Information Page
Overview
Ceribell has invested more than a decade in developing point-of-care EEG technology to improve the diagnosis and management of patients with serious neurological conditions. To protect these innovations and ensure fair competition, we have filed complaints with the U.S. International Trade Commission and the U.S. District Court in Delaware against Natus Medical Incorporated. This page provides updates and resources related to the litigation.
Ceribell Press Release
July 7, 2025
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
https://investors.ceribell.com/news-releases/news-release-details/ceribell-files-complaints-against-natus-medical-incorporated-us
Litigation Documents
ITC Notice of Institution of Investigation
ITC Press Release for Notice of Institution
Q&A
We believe the newly released Natus BrainWatch point-of-care EEG infringes on six of our patents, including patents that cover key features of our revolutionary EEG headband design. We decided to take legal action because we believe that it is necessary to protect our innovations and enable fair competition in the market. We have confidence in our case.
We believe Natus BrainWatch infringes on six Ceribell patents related to important features of our EEG headband and electrode design. Information regarding the specifics of the lawsuit is available in our press release and legal complaints against Natus, which are available on this page [or at link].
On 8/26/2025, the United States International Trade Commission (ITC) announced that the case is expected to conclude by January 2027. The target date for Administrative Law Judge’s initial determination on infringement is 9/25/26. As is typical, the District Court case has been stayed pending an ITC decision. In the meantime, it is ‘business as usual’ for Ceribell.
A U.S. District Court lawsuit can result in an award of financial damages, while an ITC complaint can lead to infringing products being blocked from importation into the U.S.
Ceribell is seeking, among other things, exclusion from the market and cease and desist orders against Natus. Those orders, if granted, would require Natus to stop importing and selling its current BrainWatch product in the United States.
We absolutely do. Since our founding in 2014, we’ve heavily invested in innovation and IP protection. Our patent portfolio reflects more than a decade of clinical development, engineering, and AI training. We are proud to have created the point-of-care EEG market.
Litigation is inherently uncertain, but we filed complaints against Natus because we have confidence in the strength of our patents.
Yes. Natus Neuro was sued in District Court for patent infringement. In that case, the court ruled that Natus Neuro had willfully infringed another company’s neurological device patents. Ultimately, Natus Neuro was required to remove its product from the market.